The Association of Anti-Ro52 Autoantibodies with Myositis and Scleroderma Autoantibodies

Frank, Mark Barton; Mccubbin, Victoria R.; Trieu, Edward P.; Wu, Yajaun; Isenberg, David; Targoff, Ira N.

doi:10.1006/jaut.1998.0265

Cited by 80 publications

(52 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-Ro52 was found to be present at a frequency of at least 15% in all antibody groups tested. This frequency appeared to be greater than previously described [18,19]. The data presented in this study demonstrate that anti-Ro52 is prevalent throughout the scleroderma supporting the hypothesis that anti-Ro52 is a general serum marker with limited linkage to a myositis phenotype or other clinical manifestations of scleroderma.…”

Section: Discussionsupporting

confidence: 77%

See 1 more Smart Citation

Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in Scleroderma?

Ferreira¹

2012

J Pulm Respir Med

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 77%

“…In our study the prevalence of anti-Ro52 antibodies was even greater than previously described [12,18,19] reaching 43.7% of the tested sera. The data presented in our study demonstrate that anti-Ro52 antibodies lack sensitivity, specificity and predictive values for pulmonary involvement diagnosis in scleroderma.…”

Section: Discussioncontrasting

confidence: 59%

Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in Scleroderma?

Ferreira¹

2012

J Pulm Respir Med

View full text Add to dashboard Cite

show abstract

“…The authors found a similar high frequency of anti-Ro52 in non-Jo-1 anti-synthetase patients [65] and in 47% of anti-PM-Scl patients. Anti-Ro52, at 25%, was the most common defined autoantibody in European patients with myositis [14••], compared with only 4% with anti-Ro60.…”

Section: New Myositis Associationsmentioning

confidence: 55%

Idiopathic inflammatory myopathy: Autoantibody update

Targoff

2002

Curr Rheumatol Rep

Self Cite

View full text Add to dashboard Cite

Several defined, specific autoantibodies have been associated with polymyositis and dermatomyositis. These include autoantibodies to at least six of the aminoacyl-transfer-ribonucleic-acid synthetases; to the signal recognition particle; to the protein complexes labeled Mi-2 and PM-Scl; and several autoantibodies, such as anti-U1nRNP and anti-Ro/SSA, that have recognized associations with other conditions. These autoantibodies are a continuing area of interest. Recent studies have involved the clinical implications of these autoantibodies, and their potential significance for etiology and pathogenesis of the disease. This report will review recent studies of myositis autoantibodies and their clinical associations, both extramuscular features, such as interstitial lung disease and aspects of the myositis itself. New myositis autoantibodies continue to emerge, which may have clinical utility. Several have been associated with dermatomyositis, including juvenile dermatomyositis, which has a low frequency of traditional myositis autoantibodies. There is also new information regarding the antigenic targets of anti-Mi-2 and anti-PM-Scl, two of the earliest recognized myositis autoantibodies. New evidence over the past few years has challenged old concepts of the relationship of autoantibodies to the pathogenesis of myositis, and has suggested potential new mechanisms for the origin of the associated autoantibodies. Despite this progress, the reason for production of the autoantibodies and their role in tissue injury remain unknown.

show abstract

“…It was recently reported in the USA that anti-SS-A was detected in 3 of 19 patients with anti-topo I-positive sera measured by DID. 17 Those previous reports did not determine the clinical characteristics of SSc patients with coexisting antitopo I and anti-SS-A. In contrast, Kuwana et al 18 showed that the frequency of Japanese SSc patients positive for anti SS-A was fairly high (37%) in anti-topo I-positive SSc patients using immunoprecipitation.They also reported that the coexistence of anti-topo I and anti-SS-A was associated with the clinical subset without severe lung disease, but they did not determine whether the patients with anti-SS-A were complicated with Sjögren's syndrome.…”

Section: Discussionmentioning

confidence: 84%

Classification of systemic sclerosis in the Japanese population based on rapid progression of skin thickening

et al. 2004

View full text Add to dashboard Cite

In general, patients with systemic sclerosis (SSc) have been classified in two clinical subsets (diffuse and limited) based on the extent of skin thickening, and the extent of skin fibrosis is closely related to the severity of organ involvement and mortality rates. In addition, there is a rapid progression of skin thickening in diffuse cutaneous SSc (dcSSc). In this study, we classified a novel subset of SSc based on the rate of skin thickening progression, and evaluated the relationship of the subset to disease severity and laboratory markers. Thirty-three patients with dcSSc were included in the study. Participants who had a modified Rodnan's total skin thickness score higher than 15 points within a year from the first symptoms were defined as having rapidly progressive SSc (RPSSc; group 1), while all the other dcSSc patients were defined as having non-RPSSc (group 2). The frequencies of interstitial lung disease and renal crisis were significantly higher in group 1 than in group 2. The frequencies of anti-topoisomerase I antibody (anti-topo I) and anti-SS-A antibody were significantly higher in group 1 than in group 2. Conversely, the frequency of anticentromere antibody was significantly higher in group 2 than in group 1. This study demonstrates the clinical significance of a new subset of SSc (defined as RPSSc), which is characterized by a markedly rapid progression of skin thickening. This new classification may be useful for predicting the prognosis of SSc at an early stage, so that patients who should receive aggressive therapy with immunosuppressants might be identified.

show abstract

The Association of Anti-Ro52 Autoantibodies with Myositis and Scleroderma Autoantibodies

Cited by 80 publications

References 18 publications

Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in Scleroderma?

Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in Scleroderma?

Idiopathic inflammatory myopathy: Autoantibody update

Classification of systemic sclerosis in the Japanese population based on rapid progression of skin thickening

Contact Info

Product

Resources

About